Arabic
Chinese (Simplified)
English
French
German
Portuguese
Russian
Spanish
The State of Longevity 2021
By Daragh Campbell
2021 demonstrated that research into antiaging therapies is going from strength-to-strength, and our review of longevity clinical trials shows this clearly. As different areas of research continue to gain traction (cellular reprogramming, in particular), we wanted to analyse exactly how the longevity clinical trial market performed last year.
In order to assess clinical trial data across 2021, we interrogated the Longevity.Technology database, which consists of over 250 longevity companies (and growing all the time!). This was used to assess new progress made across the year, throughout the clinical trial market, in addition to progress made in different segments of the longevity sector.
We then compiled data from PubMed to gain an overview of the frequency of publications and trials in 2021 in comparison with 2011. This data was input into a table to compare the increase in both “longevity” related studies in 2011 and 2021. Finally, to display drug target clinical trial progression across 2021, we spotlighted 12 companies and used data from the Longevity. Technology database to give insights into progress in longevity therapeutics.
Read book “here”
